Literature DB >> 9880116

Pituitary diseases in pregnancy.

M E Molitch1.   

Abstract

Pituitary adenomas are the most common pituitary disorder affecting pregnancy, and prolactinomas are the most common of the hormone-secreting pituitary adenomas. Hyperprolactinemia must be corrected to allow ovulation and fertility. Bromocriptine has been shown to be safe for use during early gestation. There is less than a 2% risk of microprolactinoma enlargement during pregnancy but a greater than 15% risk of symptomatic enlargement of a macroprolactinoma. Treatment options for patients with macroadenomas include stopping bromocriptine when pregnancy is diagnosed and reinstituting with tumor enlargement, continuous bromocriptine throughout pregnancy, and prepregnancy tumor debulking by surgery. The diagnosis of acromegaly may be difficult to make during pregnancy and relies, in part, on the persistence of the normal pulsatile secretion of growth hormone and loss of this secretory characteristic with a tumor. The growth hormone oversecretion may exacerbate tendencies to gestational diabetes, fluid retention, and hypertension. Treatment for acromegaly and other tumors generally may be deferred until after delivery. There are rare reports of enlargement of clinically nonfunctioning and growth hormone secreting tumors during pregnancy, and surveillance is needed. Tumors may need to be differentiated from lymphocytic hypophysitis. Patients with chronic hypopituitarism usually will need treatment with gonadotropins or pulsatile GnRH to become pregnant and may need increased steroid coverage during labor and delivery. Hypopituitarism developing during pregnancy is usually caused by lymphocytic hypophysitis and usually also will require steroid replacement therapy. Hypopituitarism arising postpartum may be caused by either lymphocytic hypophysitis or Sheehan's syndrome, and the latter may present as an acute or chronic syndrome. Borderline diabetes insipidus may manifest during pregnancy because of increased vasopressin degradation caused by markedly increased levels of placental vasopressinase. Treatment with desmopressin usually is satisfactory. Patients presenting with either anterior or posterior pituitary insufficiency in the peripartum period should always be evaluated for function of the other portion of the pituitary.

Entities:  

Mesh:

Year:  1998        PMID: 9880116     DOI: 10.1016/s0146-0005(98)80026-8

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  8 in total

Review 1.  Sheehan's syndrome.

Authors:  Fahrettin Keleştimur
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 2.  Prolactinomas and pregnancy.

Authors:  Marcello Delano Bronstein
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 3.  Imaging neurological emergencies in pregnancy and puerperium.

Authors:  Matthew A Haber; Diego Nunez
Journal:  Emerg Radiol       Date:  2018-07-20

4.  Developed diplopia and ptosis due to a nonfunctioning pituitary macroadenoma during pregnancy.

Authors:  Hye-Ran Lee; Ji-Eun Song; Keun-Young Lee
Journal:  Obstet Gynecol Sci       Date:  2014-01-16

5.  Dilated Cardiomyopathy Reversibility in Sheehan's Syndrome: A Case Report.

Authors:  Maria Luíza Barbosa Fernandes Dourado; Taís Paiva da Costa; Márcia Sampaio de Carvalho; Carlos Geraldo Guerreiro de Moura
Journal:  Arq Bras Cardiol       Date:  2021-02       Impact factor: 2.000

6.  Sheehan's Syndrome A Case Report and Literature Review.

Authors:  S Errarhay; I Kamaoui; C Bouchikhi; H Châara; H Bouguern; S Tizniti; A Melhouf; A Banani
Journal:  Libyan J Med       Date:  2009-06-01       Impact factor: 1.657

7.  Developed diplopia due to a pituitary macroadenoma during pregnancy.

Authors:  Houda Ennaifer; Manel Jemel; Hejer Kandar; Wafa Grira; Ines Kammoun; Leila Ben Salem
Journal:  Pan Afr Med J       Date:  2018-01-17

8.  Transient diabetes insipidus in pregnancy.

Authors:  Pedro Marques; Kavinga Gunawardana; Ashley Grossman
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2015-09-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.